TRIPLE NEGATIVE BREAST CANCER

This study is testing an investigational drug called SKB264 for people with advanced triple-negative breast cancer that has spread or returned and has not responded to at least two prior standard treatments. The goal is to see if SKB264 works better than other chemotherapy option…

This early-stage study is testing a new drug called BT5528, both alone and combined with another cancer drug (nivolumab), in people with advanced solid tumors. The main goals are to find a safe dose and see what side effects occur. Researchers will also check if the drug helps sh…

This early-stage study is testing the safety of a new experimental cancer vaccine called PeptiCRAd-1 when given alongside the immunotherapy drug pembrolizumab. The trial involves 15 adults with various advanced solid tumors that have specific markers. Researchers will inject the …

This study is testing whether a new drug called FDA018-ADC works better than standard chemotherapy for people with advanced triple-negative breast cancer that has come back or stopped responding to a common type of chemotherapy. It will involve about 350 participants whose cancer…

This study tests whether a combination of three drugs (pembrolizumab, carboplatin, and paclitaxel) given before surgery can completely eliminate cancer in patients with early-stage triple-negative breast cancer. The trial involves 30 participants who haven't had previous cancer t…

This study is testing whether combining two existing drugs—ribociclib and bicalutamide—can help control advanced triple-negative breast cancer that has a specific marker called the androgen receptor. The goal is to see if the combination is safe and can slow or shrink tumors. The…

This study tested whether giving two chemotherapy drugs (carboplatin and nab-paclitaxel) before surgery could effectively shrink tumors in patients with a hard-to-treat type of breast cancer called triple-negative breast cancer. The goal was to see if this approach could complete…

This study is testing whether a newer drug called sacituzumab govitecan works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread and hasn't been treated before. It involves about 623 participants who will be randomly assigned …

This study is testing whether a new drug called BL-B01D1 works better than standard chemotherapy for people with advanced triple-negative breast cancer that has spread and stopped responding to a common type of chemo (taxanes). About 418 adults will be randomly assigned to receiv…

This study is testing an experimental drug called Dato-DXd in Chinese patients with advanced cancers that have stopped responding to standard treatments. The trial focuses on non-small cell lung cancer and triple-negative breast cancer, enrolling 119 participants who will receive…

This study is testing whether combining three drugs—cisplatin, romidepsin, and nivolumab—is safe and effective for controlling advanced breast cancer that has spread or returned. It focuses on two specific groups: patients with triple-negative breast cancer or those with a BRCA g…

This study is for people with HER2-negative breast cancer who still have cancer cells after initial (neoadjuvant) chemotherapy, putting them at high risk of the cancer coming back. It compares a newer, targeted drug called sacituzumab govitecan against standard follow-up treatmen…

This study is testing a personalized cell therapy called LN-145 for patients with advanced cancers that have stopped responding to standard treatments. Doctors collect a patient's own immune cells from their tumor, grow large numbers of them in a lab, and then infuse them back in…

This study is testing a new combination of two immunotherapy drugs (tiragolumab and atezolizumab) with standard chemotherapy for triple-negative breast cancer. It aims to see if this three-part treatment is safe and more effective at shrinking tumors before surgery for early-stag…

This early-phase study is testing a personalized cell therapy for advanced triple-negative breast cancer that has returned or stopped responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to recognize cancer, and infuse them back to at…

This is the first time a new drug called DS-1062a is being tested in people. The main goal is to find a safe and tolerable dose for patients with advanced solid tumors, including lung and breast cancers, that have not responded to standard treatments. The study will also test if …

This study is testing whether adding a targeted dose of radiation to the breast tumor before starting standard chemotherapy and an immunotherapy drug (pembrolizumab) makes the treatment more effective. It is for people with breast cancer that has spread to lymph nodes and is eith…

This study aimed to test the safety and effectiveness of a two-drug combination (Ezabenlimab and BI 907828) for people with advanced, hard-to-treat cancers that had spread. It was designed for adults with specific types of soft tissue sarcoma, lung, breast, colorectal, or biliary…

This early-stage study is testing an experimental drug called ABBV-400 in adults with advanced solid tumors that have spread or cannot be removed by surgery. It includes eight specific cancer types, such as liver, pancreatic, and certain breast cancers. The main goals are to chec…

This is a first-in-human study to find a safe dose and see how the body processes a new oral drug called ATV-1601. It is being tested in adults with advanced solid tumors, including certain breast cancers, that have a specific genetic change called an AKT1 E17K mutation. The main…

This study is testing a new three-drug combination given before surgery for early-stage triple-negative breast cancer (TNBC), an aggressive type. The goal is to see if adding two newer drugs (sintilimab and anlotinib) to standard chemotherapy can better shrink or eliminate the tu…

This study is testing a new drug called azenosertib, combined with two existing cancer drugs, for people with advanced triple-negative breast cancer that has spread. The main goals are to find a safe dose and see if the combination makes tumors shrink. About 78 participants will …

This early-stage study is testing the safety of a new cancer vaccine called PVX-410, given alone and with an immunotherapy drug (pembrolizumab), in 20 patients with advanced triple-negative breast cancer. The goal is to see if the combination can safely help the patient's own imm…

This study is testing if a new drug combination works better than current standard treatments for people with a hard-to-treat type of advanced breast cancer. It involves 443 adults with triple-negative breast cancer that has spread and who have not yet received treatment for thei…

This is an early-stage study testing a new drug called DKY709, both alone and combined with another drug (PDR001), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goal is to find safe doses and understand side effects. Researcher…

This study is testing whether a three-part treatment is safe and can help control advanced triple-negative breast cancer that has spread and hasn't responded well to standard immunotherapy. The treatment combines two drugs—one that helps the immune system fight cancer and another…

This study is testing a new drug called BNT327, given alongside standard chemotherapy, for people with advanced triple-negative breast cancer. The main goals are to see if the combination is safe and if it helps shrink tumors. The trial will enroll about 83 adults who have either…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study is testing the safety of a drug called niraparib when given alongside standard radiation therapy after surgery. It involves 21 adults with triple-negative breast cancer who still have some cancer cells left after initial treatment. The goal is to see if this combinatio…

This is an early-stage study testing a new antibody drug called IMT-009 in people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, and see if the drug helps shrink tum…

This early-stage trial is testing a new antibody drug called acasunlimab (GEN1046) for people with advanced solid tumors. The study first aims to find safe doses, then tests how well those doses work when given alone or combined with other cancer drugs. All 429 participants will …

This study is testing whether using a precise, high-dose radiation treatment on a few new or growing tumors can help people with advanced lung or breast cancer stay on their current medications longer. It aims to see if this approach can delay the cancer from getting worse. The t…

This study aims to find patterns in blood proteins and other markers that might predict if triple-negative breast cancer will spread or return after initial treatment. Researchers will collect blood samples from 90 patients at different points during their standard cancer care to…

This study aims to find a way to predict which patients with triple-negative breast cancer are most likely to have their cancer return after treatment. Researchers will check the blood of 15 patients during their radiation therapy, looking for specific signals (cytokines) that mi…

This study aims to find out if simple blood tests and tumor tissue analysis can help predict how patients with triple negative breast cancer will respond to treatment and their risk of the cancer returning. Researchers will observe 90 patients to see if certain blood cell counts …

This study aims to understand how doctors currently treat advanced triple-negative breast cancer in real-world settings outside the United States. Researchers will review medical records of 760 patients from Canada, the UK, France, and Spain to document treatment patterns and pat…